The Diagnosis: Radiation-Associated Angiosarcoma

At the time of presentation, a 4-mm lesional punch biopsy was obtained (Figure), which revealed an epithelioid neoplasm within the dermis expressing CD31 and CD34, and staining negatively for S-100, CD45, and estrogen and progesterone receptors. The histologic and immunophenotypic findings were compatible with the diagnosis of angiosarcoma. Given the patient’s history of radiation for breast carcinoma several years ago, this tumor was consistent with radiation-associated angiosarcoma (RAAS).

Development of secondary angiosarcoma has been linked to both prior radiation (RAAS) and chronic lymphedema (Stewart-Treves syndrome).¹ Radiation-associated angiosarcoma is defined as a “pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field.”² The incidence of RAAS is estimated to be 0.9 per 1000 individuals following radiation treatment of breast cancer over the subsequent 15 years and a mean time from radiation to development of 7 years.¹ Incidence is expected to increase in the future due to improved likelihood of surviving early-stage breast carcinoma and the increased use of external beam radiation therapy for management of breast cancer.

Differentiating between primary and secondary angiosarcoma of the breast is important. Although primary breast angiosarcoma usually arises in women aged 30 to 40 years, RAAS tends to arise in older women (mean age, 68 years) and is seen only in those women with prior radiation.² Additionally, high-level amplification of MYC, a known photo-oncogene, on chromosome 8 is a key genetic alteration of RAAS that helps to distinguish it from primary angiosarcoma, though this variance may be present in only half of RAAS cases.³ Immunohistochemical analysis of tumor cells for MYC expression correlates well with this amplification and also is helpful in distinguishing atypical vascular lesions from RAAS.⁴ Atypical vascular lesions, similar to RAAS, occur years after radiation exposure and may have a similar clinical presentation. Atypical vascular lesions do not progress to angiosarcoma in reported cases, but clinical and histologic overlap with RAAS make the diagnosis difficult.⁵ In these cases, analysis with fluorescence in situ hybridization or immunohistochemistry for the MYC amplification is important to differentiate these tumors.⁶

At the time of presentation, the majority of patients with RAAS of the breast have localized disease, often with a variable presentation. In all known cases, there have been skin changes present, emphasizing the importance of both patient and clinician vigilance on a regular basis in at-risk individuals. In one study, the most common presentation was breast ecchymosis, which was observed in 55% of patients.⁷ These lesions involve the dermis and are commonly mistaken for benign conditions such as infection or hemorrhage.² In 2 other studies, RAAS most often manifested as a skin nodule or apparent tumor, closely followed by either a rash or bruiselike presentation.^1,2

The overall recommendation for management of patients with ecchymotic skin lesions in previously irradiated regions is to obtain a biopsy specimen for tissue diagnosis. Although there is no standard of care for the management of RAAS, a multidisciplinary approach involving specialists from oncology, surgical oncology, and radiation oncology is recommended. Most often, radical surgery encompassing both the breast parenchyma and the at-risk radiated skin is performed. Extensive surgery has demonstrated the best survival benefits compared to mastectomy alone.⁷ Chemotherapeutics also may be used as adjuncts to surgery, which have been determined to decrease local recurrence rates but have no proven survival benefits.² Adverse prognostic factors for survival are tumor size greater than 10 cm and development of local and/or distant metastases.² Following the diagnosis of RAAS, our patient underwent radical mastectomy with adjuvant chemotherapy and remained disease free 6 months after surgery.

In summary, RAAS is a well-known, albeit relatively uncommon, consequence of radiation therapy. Dermatologists, oncologists, and primary care providers play an important role in recognizing this entity when evaluating patients with ecchymotic lesions as well as nodules or tumors within an irradiated field. Biopsy should be obtained promptly to prevent delay in diagnosis and to expedite referral to appropriate specialists for further evaluation and treatment.

The Diagnosis: Radiation-Associated Angiosarcoma

At the time of presentation, a 4-mm lesional punch biopsy was obtained (Figure), which revealed an epithelioid neoplasm within the dermis expressing CD31 and CD34, and staining negatively for S-100, CD45, and estrogen and progesterone receptors. The histologic and immunophenotypic findings were compatible with the diagnosis of angiosarcoma. Given the patient’s history of radiation for breast carcinoma several years ago, this tumor was consistent with radiation-associated angiosarcoma (RAAS).

Development of secondary angiosarcoma has been linked to both prior radiation (RAAS) and chronic lymphedema (Stewart-Treves syndrome).¹ Radiation-associated angiosarcoma is defined as a “pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field.”² The incidence of RAAS is estimated to be 0.9 per 1000 individuals following radiation treatment of breast cancer over the subsequent 15 years and a mean time from radiation to development of 7 years.¹ Incidence is expected to increase in the future due to improved likelihood of surviving early-stage breast carcinoma and the increased use of external beam radiation therapy for management of breast cancer.

Differentiating between primary and secondary angiosarcoma of the breast is important. Although primary breast angiosarcoma usually arises in women aged 30 to 40 years, RAAS tends to arise in older women (mean age, 68 years) and is seen only in those women with prior radiation.² Additionally, high-level amplification of MYC, a known photo-oncogene, on chromosome 8 is a key genetic alteration of RAAS that helps to distinguish it from primary angiosarcoma, though this variance may be present in only half of RAAS cases.³ Immunohistochemical analysis of tumor cells for MYC expression correlates well with this amplification and also is helpful in distinguishing atypical vascular lesions from RAAS.⁴ Atypical vascular lesions, similar to RAAS, occur years after radiation exposure and may have a similar clinical presentation. Atypical vascular lesions do not progress to angiosarcoma in reported cases, but clinical and histologic overlap with RAAS make the diagnosis difficult.⁵ In these cases, analysis with fluorescence in situ hybridization or immunohistochemistry for the MYC amplification is important to differentiate these tumors.⁶

At the time of presentation, the majority of patients with RAAS of the breast have localized disease, often with a variable presentation. In all known cases, there have been skin changes present, emphasizing the importance of both patient and clinician vigilance on a regular basis in at-risk individuals. In one study, the most common presentation was breast ecchymosis, which was observed in 55% of patients.⁷ These lesions involve the dermis and are commonly mistaken for benign conditions such as infection or hemorrhage.² In 2 other studies, RAAS most often manifested as a skin nodule or apparent tumor, closely followed by either a rash or bruiselike presentation.^1,2

The overall recommendation for management of patients with ecchymotic skin lesions in previously irradiated regions is to obtain a biopsy specimen for tissue diagnosis. Although there is no standard of care for the management of RAAS, a multidisciplinary approach involving specialists from oncology, surgical oncology, and radiation oncology is recommended. Most often, radical surgery encompassing both the breast parenchyma and the at-risk radiated skin is performed. Extensive surgery has demonstrated the best survival benefits compared to mastectomy alone.⁷ Chemotherapeutics also may be used as adjuncts to surgery, which have been determined to decrease local recurrence rates but have no proven survival benefits.² Adverse prognostic factors for survival are tumor size greater than 10 cm and development of local and/or distant metastases.² Following the diagnosis of RAAS, our patient underwent radical mastectomy with adjuvant chemotherapy and remained disease free 6 months after surgery.

In summary, RAAS is a well-known, albeit relatively uncommon, consequence of radiation therapy. Dermatologists, oncologists, and primary care providers play an important role in recognizing this entity when evaluating patients with ecchymotic lesions as well as nodules or tumors within an irradiated field. Biopsy should be obtained promptly to prevent delay in diagnosis and to expedite referral to appropriate specialists for further evaluation and treatment.

The Diagnosis: Radiation-Associated Angiosarcoma

At the time of presentation, a 4-mm lesional punch biopsy was obtained (Figure), which revealed an epithelioid neoplasm within the dermis expressing CD31 and CD34, and staining negatively for S-100, CD45, and estrogen and progesterone receptors. The histologic and immunophenotypic findings were compatible with the diagnosis of angiosarcoma. Given the patient’s history of radiation for breast carcinoma several years ago, this tumor was consistent with radiation-associated angiosarcoma (RAAS).

Development of secondary angiosarcoma has been linked to both prior radiation (RAAS) and chronic lymphedema (Stewart-Treves syndrome).¹ Radiation-associated angiosarcoma is defined as a “pathologically confirmed breast or chest wall angiosarcoma arising within a previously irradiated field.”² The incidence of RAAS is estimated to be 0.9 per 1000 individuals following radiation treatment of breast cancer over the subsequent 15 years and a mean time from radiation to development of 7 years.¹ Incidence is expected to increase in the future due to improved likelihood of surviving early-stage breast carcinoma and the increased use of external beam radiation therapy for management of breast cancer.

Differentiating between primary and secondary angiosarcoma of the breast is important. Although primary breast angiosarcoma usually arises in women aged 30 to 40 years, RAAS tends to arise in older women (mean age, 68 years) and is seen only in those women with prior radiation.² Additionally, high-level amplification of MYC, a known photo-oncogene, on chromosome 8 is a key genetic alteration of RAAS that helps to distinguish it from primary angiosarcoma, though this variance may be present in only half of RAAS cases.³ Immunohistochemical analysis of tumor cells for MYC expression correlates well with this amplification and also is helpful in distinguishing atypical vascular lesions from RAAS.⁴ Atypical vascular lesions, similar to RAAS, occur years after radiation exposure and may have a similar clinical presentation. Atypical vascular lesions do not progress to angiosarcoma in reported cases, but clinical and histologic overlap with RAAS make the diagnosis difficult.⁵ In these cases, analysis with fluorescence in situ hybridization or immunohistochemistry for the MYC amplification is important to differentiate these tumors.⁶

At the time of presentation, the majority of patients with RAAS of the breast have localized disease, often with a variable presentation. In all known cases, there have been skin changes present, emphasizing the importance of both patient and clinician vigilance on a regular basis in at-risk individuals. In one study, the most common presentation was breast ecchymosis, which was observed in 55% of patients.⁷ These lesions involve the dermis and are commonly mistaken for benign conditions such as infection or hemorrhage.² In 2 other studies, RAAS most often manifested as a skin nodule or apparent tumor, closely followed by either a rash or bruiselike presentation.^1,2

The overall recommendation for management of patients with ecchymotic skin lesions in previously irradiated regions is to obtain a biopsy specimen for tissue diagnosis. Although there is no standard of care for the management of RAAS, a multidisciplinary approach involving specialists from oncology, surgical oncology, and radiation oncology is recommended. Most often, radical surgery encompassing both the breast parenchyma and the at-risk radiated skin is performed. Extensive surgery has demonstrated the best survival benefits compared to mastectomy alone.⁷ Chemotherapeutics also may be used as adjuncts to surgery, which have been determined to decrease local recurrence rates but have no proven survival benefits.² Adverse prognostic factors for survival are tumor size greater than 10 cm and development of local and/or distant metastases.² Following the diagnosis of RAAS, our patient underwent radical mastectomy with adjuvant chemotherapy and remained disease free 6 months after surgery.

In summary, RAAS is a well-known, albeit relatively uncommon, consequence of radiation therapy. Dermatologists, oncologists, and primary care providers play an important role in recognizing this entity when evaluating patients with ecchymotic lesions as well as nodules or tumors within an irradiated field. Biopsy should be obtained promptly to prevent delay in diagnosis and to expedite referral to appropriate specialists for further evaluation and treatment.

Background: Service handovers contribute to discontinuity of care in hospitalized patients. Research on hospitalist service handovers is limited, and no previous study has examined the service handover from the patient’s perspective.

Study design: Interview-based, qualitative analysis.

Setting: Urban academic medical center.

Synopsis: Researchers interviewed 40 hospitalized patients using a semi-structured nine-question interview regarding their attending hospitalist service change. The constant comparative method was used to identify recurrent themes in patient responses. The research team identified six themes representative of patient concerns during service change: physician-patient communication, transparency in communication, hospitalist-specialist communication, new opportunities due to transition, bedside manner, and indifference toward the transition.

Authors used the six themes to develop a model for the ideal service handover, utilizing open lines of communication, facilitated by multiple modalities and disciplines, and recognizing the patient’s role as the primary stakeholder in the transition of care.

Bottom line: Incorporating patients’ perspective presents an opportunity to improve communication and efficiency during hospitalist service transitions.

Citation: Wray CM, Farnan JM, Arora VM, Meltzer DO. A qualitative analysis of patients’ experience with hospitalist service handovers [published online ahead of print May 11, 2016]. J Hosp Med. doi:10.1002/jhm.2608.

Background: Service handovers contribute to discontinuity of care in hospitalized patients. Research on hospitalist service handovers is limited, and no previous study has examined the service handover from the patient’s perspective.

Study design: Interview-based, qualitative analysis.

Setting: Urban academic medical center.

Synopsis: Researchers interviewed 40 hospitalized patients using a semi-structured nine-question interview regarding their attending hospitalist service change. The constant comparative method was used to identify recurrent themes in patient responses. The research team identified six themes representative of patient concerns during service change: physician-patient communication, transparency in communication, hospitalist-specialist communication, new opportunities due to transition, bedside manner, and indifference toward the transition.

Authors used the six themes to develop a model for the ideal service handover, utilizing open lines of communication, facilitated by multiple modalities and disciplines, and recognizing the patient’s role as the primary stakeholder in the transition of care.

Bottom line: Incorporating patients’ perspective presents an opportunity to improve communication and efficiency during hospitalist service transitions.

Citation: Wray CM, Farnan JM, Arora VM, Meltzer DO. A qualitative analysis of patients’ experience with hospitalist service handovers [published online ahead of print May 11, 2016]. J Hosp Med. doi:10.1002/jhm.2608.

Background: Service handovers contribute to discontinuity of care in hospitalized patients. Research on hospitalist service handovers is limited, and no previous study has examined the service handover from the patient’s perspective.

Study design: Interview-based, qualitative analysis.

Setting: Urban academic medical center.

Synopsis: Researchers interviewed 40 hospitalized patients using a semi-structured nine-question interview regarding their attending hospitalist service change. The constant comparative method was used to identify recurrent themes in patient responses. The research team identified six themes representative of patient concerns during service change: physician-patient communication, transparency in communication, hospitalist-specialist communication, new opportunities due to transition, bedside manner, and indifference toward the transition.

Authors used the six themes to develop a model for the ideal service handover, utilizing open lines of communication, facilitated by multiple modalities and disciplines, and recognizing the patient’s role as the primary stakeholder in the transition of care.

Bottom line: Incorporating patients’ perspective presents an opportunity to improve communication and efficiency during hospitalist service transitions.

Citation: Wray CM, Farnan JM, Arora VM, Meltzer DO. A qualitative analysis of patients’ experience with hospitalist service handovers [published online ahead of print May 11, 2016]. J Hosp Med. doi:10.1002/jhm.2608.

Background: For patients with atrial fibrillation and history of intracranial hemorrhage (ICH), the risk of further ICH and the benefit of antithrombotic agents for stroke risk reduction remain unclear.

Study design: Retrospective cohort study.

Setting: National Health Research Institutes, Taiwan.

Synopsis: Using the National Health Insurance Research Database in Taiwan, researchers identified 307,640 patients with atrial fibrillation and a CHA2DS2-VASc score >/= 2. Of this group, 12,917 patients with a history of ICH were identified and separated into three groups: no treatment, antiplatelet treatment, or warfarin. Among the no treatment group, the rate of ICH and ischemic cerebrovascular accident were 4.2 and 5.8 per 100 person-years, respectively. Among patients on antiplatelet therapy, the rates were 5.3% and 5.2%, respectively. Among patients on warfarin, the number needed to treat (NNT) for preventing one ischemic stroke was lower than the number needed to harm (NNH) for producing one ICH among patients with a CHA2DS2-VASc score >/= 6. In patients with lower CHA2DS2-VASc scores, the NNT was higher than NNH.

Bottom line: Treatment with warfarin may benefit patients with atrial fibrillation and prior ICH with CHA2DS2-VASc scores >/= 6, but risk likely outweighs benefit in patients with lower scores.

Citation: Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation. 2016;133(16):1540-1547.

Background: For patients with atrial fibrillation and history of intracranial hemorrhage (ICH), the risk of further ICH and the benefit of antithrombotic agents for stroke risk reduction remain unclear.

Study design: Retrospective cohort study.

Setting: National Health Research Institutes, Taiwan.

Synopsis: Using the National Health Insurance Research Database in Taiwan, researchers identified 307,640 patients with atrial fibrillation and a CHA2DS2-VASc score >/= 2. Of this group, 12,917 patients with a history of ICH were identified and separated into three groups: no treatment, antiplatelet treatment, or warfarin. Among the no treatment group, the rate of ICH and ischemic cerebrovascular accident were 4.2 and 5.8 per 100 person-years, respectively. Among patients on antiplatelet therapy, the rates were 5.3% and 5.2%, respectively. Among patients on warfarin, the number needed to treat (NNT) for preventing one ischemic stroke was lower than the number needed to harm (NNH) for producing one ICH among patients with a CHA2DS2-VASc score >/= 6. In patients with lower CHA2DS2-VASc scores, the NNT was higher than NNH.

Bottom line: Treatment with warfarin may benefit patients with atrial fibrillation and prior ICH with CHA2DS2-VASc scores >/= 6, but risk likely outweighs benefit in patients with lower scores.

Citation: Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation. 2016;133(16):1540-1547.

Background: For patients with atrial fibrillation and history of intracranial hemorrhage (ICH), the risk of further ICH and the benefit of antithrombotic agents for stroke risk reduction remain unclear.

Study design: Retrospective cohort study.

Setting: National Health Research Institutes, Taiwan.

Synopsis: Using the National Health Insurance Research Database in Taiwan, researchers identified 307,640 patients with atrial fibrillation and a CHA2DS2-VASc score >/= 2. Of this group, 12,917 patients with a history of ICH were identified and separated into three groups: no treatment, antiplatelet treatment, or warfarin. Among the no treatment group, the rate of ICH and ischemic cerebrovascular accident were 4.2 and 5.8 per 100 person-years, respectively. Among patients on antiplatelet therapy, the rates were 5.3% and 5.2%, respectively. Among patients on warfarin, the number needed to treat (NNT) for preventing one ischemic stroke was lower than the number needed to harm (NNH) for producing one ICH among patients with a CHA2DS2-VASc score >/= 6. In patients with lower CHA2DS2-VASc scores, the NNT was higher than NNH.

Bottom line: Treatment with warfarin may benefit patients with atrial fibrillation and prior ICH with CHA2DS2-VASc scores >/= 6, but risk likely outweighs benefit in patients with lower scores.

Citation: Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation. 2016;133(16):1540-1547.

Catriona Jamieson, MD, PhD

Photo courtesy of the University

of California San Diego

Researchers say they have identified RNA-based biomarkers that distinguish normal, aged hematopoietic stem and progenitor cells (HSPCs) from leukemia stem cells (LSCs) associated with secondary acute myeloid leukemia (sAML).

The team believes their discovery may provide a new way to predict leukemic relapse and identify targets for drug development.

Catriona Jamieson, MD, PhD, of the University of California San Diego in La Jolla, and her colleagues described the discovery in Cell Stem Cell.

The researchers noted that age-related hematopoietic stem cell exhaustion and myeloid-lineage skewing promote the transformation of hematopoietic progenitors into therapy-resistant LSCs in sAML. However, the contribution of RNA processing alterations to HSPC aging and LSC generation remains unclear.

With this study, Dr Jamieson and her colleagues discovered RNA splice isoform expression patterns that distinguished normal, aged HSPCs from sAML LSCs.

The team said the aged HSPCs displayed pro-apoptotic BCL2 splice isoform switching, while sAML LSCs favored pro-survival expression of BCL2L1 (BCL-XL).

“These splicing signatures could potentially be used as clinical biomarkers to detect blood stem cells that show signs of early aging or leukemia and to monitor patient responses to treatment,” said study author Leslie Crews, PhD, of the University of California San Diego.

“By being able to distinguish benign from malignant aging based on distinctive RNA splicing patterns, we can develop therapeutic strategies that selectively target leukemia stem cells while sparing normal hematopoietic stem cells,” Dr Jamieson added.

In fact, she and her colleagues were able to show that treatment with a pharmacologic splicing modulator known as 17S-FD-895 could eradicate sAML LSCs while sparing normal HSPCs. The compound reversed pro-survival splice isoform switching and impaired LSC maintenance.

“Our findings show that RNA splicing is a unique therapeutic vulnerability for secondary AML,” Dr Jamieson said. “RNA-splicing-targeted therapies may be a potent and selective way to clear leukemia stem cells and prevent relapse.”

Catriona Jamieson, MD, PhD

Photo courtesy of the University

of California San Diego

Researchers say they have identified RNA-based biomarkers that distinguish normal, aged hematopoietic stem and progenitor cells (HSPCs) from leukemia stem cells (LSCs) associated with secondary acute myeloid leukemia (sAML).

The team believes their discovery may provide a new way to predict leukemic relapse and identify targets for drug development.

Catriona Jamieson, MD, PhD, of the University of California San Diego in La Jolla, and her colleagues described the discovery in Cell Stem Cell.

The researchers noted that age-related hematopoietic stem cell exhaustion and myeloid-lineage skewing promote the transformation of hematopoietic progenitors into therapy-resistant LSCs in sAML. However, the contribution of RNA processing alterations to HSPC aging and LSC generation remains unclear.

With this study, Dr Jamieson and her colleagues discovered RNA splice isoform expression patterns that distinguished normal, aged HSPCs from sAML LSCs.

The team said the aged HSPCs displayed pro-apoptotic BCL2 splice isoform switching, while sAML LSCs favored pro-survival expression of BCL2L1 (BCL-XL).

“These splicing signatures could potentially be used as clinical biomarkers to detect blood stem cells that show signs of early aging or leukemia and to monitor patient responses to treatment,” said study author Leslie Crews, PhD, of the University of California San Diego.

“By being able to distinguish benign from malignant aging based on distinctive RNA splicing patterns, we can develop therapeutic strategies that selectively target leukemia stem cells while sparing normal hematopoietic stem cells,” Dr Jamieson added.

In fact, she and her colleagues were able to show that treatment with a pharmacologic splicing modulator known as 17S-FD-895 could eradicate sAML LSCs while sparing normal HSPCs. The compound reversed pro-survival splice isoform switching and impaired LSC maintenance.

“Our findings show that RNA splicing is a unique therapeutic vulnerability for secondary AML,” Dr Jamieson said. “RNA-splicing-targeted therapies may be a potent and selective way to clear leukemia stem cells and prevent relapse.”

Catriona Jamieson, MD, PhD

Photo courtesy of the University

of California San Diego

Researchers say they have identified RNA-based biomarkers that distinguish normal, aged hematopoietic stem and progenitor cells (HSPCs) from leukemia stem cells (LSCs) associated with secondary acute myeloid leukemia (sAML).

The team believes their discovery may provide a new way to predict leukemic relapse and identify targets for drug development.

Catriona Jamieson, MD, PhD, of the University of California San Diego in La Jolla, and her colleagues described the discovery in Cell Stem Cell.

The researchers noted that age-related hematopoietic stem cell exhaustion and myeloid-lineage skewing promote the transformation of hematopoietic progenitors into therapy-resistant LSCs in sAML. However, the contribution of RNA processing alterations to HSPC aging and LSC generation remains unclear.

With this study, Dr Jamieson and her colleagues discovered RNA splice isoform expression patterns that distinguished normal, aged HSPCs from sAML LSCs.

The team said the aged HSPCs displayed pro-apoptotic BCL2 splice isoform switching, while sAML LSCs favored pro-survival expression of BCL2L1 (BCL-XL).

“These splicing signatures could potentially be used as clinical biomarkers to detect blood stem cells that show signs of early aging or leukemia and to monitor patient responses to treatment,” said study author Leslie Crews, PhD, of the University of California San Diego.

“By being able to distinguish benign from malignant aging based on distinctive RNA splicing patterns, we can develop therapeutic strategies that selectively target leukemia stem cells while sparing normal hematopoietic stem cells,” Dr Jamieson added.

In fact, she and her colleagues were able to show that treatment with a pharmacologic splicing modulator known as 17S-FD-895 could eradicate sAML LSCs while sparing normal HSPCs. The compound reversed pro-survival splice isoform switching and impaired LSC maintenance.

“Our findings show that RNA splicing is a unique therapeutic vulnerability for secondary AML,” Dr Jamieson said. “RNA-splicing-targeted therapies may be a potent and selective way to clear leukemia stem cells and prevent relapse.”

Daratumumab (Darzalex)

Photo courtesy of Janssen

Results of the phase 3 CASTOR trial suggest that adding daratumumab to treatment with bortezomib and dexamethasone can improve progression-free survival (PFS) in patients with previously treated multiple myeloma (MM).

Compared to patients who received only bortezomib and dexamethasone, those who received daratumumab as well had a higher response rate and longer PFS, but they also had a higher incidence of grade 3/4 adverse events (AEs).

These results were recently published in NEJM. They were previously presented at the 2016 ASCO Annual Meeting. The CASTOR trial was funded by Janssen Research & Development.

The trial enrolled 498 patients with relapsed or relapsed and refractory MM. Patients were randomized to receive bortezomib (1.3 mg/m²) and dexamethasone (20 mg) alone (control arm) or in combination with daratumumab (16 mg/kg).

Baseline characteristics were well balanced between the treatment arms. Across both groups, the median patient age was 64 (range, 30 to 88), the median time since MM diagnosis was 3.8 years, and the patients had received a median of 2 (range, 1 to 10) previous lines of therapy.

Efficacy

The overall response rate was significantly higher in the daratumumab arm than the control arm—82.9% and 63.2%, respectively (P<0.001). The rate of complete response or better was higher in the daratumumab arm as well—19.2% and 9.0%, respectively (P=0.001).

After a median follow-up of 7.4 months, the median PFS was not reached in the daratumumab arm and was 7.2 months in the control arm (hazard ratio=0.39, P<0.001). The estimated 12-month PFS was 60.7% and 26.9%, respectively.

Overall survival was not reached in either treatment arm.

This trial was unblinded after meeting its primary endpoint of improved PFS in this interim analysis. Based on the recommendation of an independent data monitoring committee, patients in the control arm were offered the option to receive daratumumab following confirmed disease progression.

Safety

AEs occurred in 98.8% of patients in the daratumumab arm and 95.4% of patients in the control arm. Grade 3/4 AEs occurred in 76.1% and 62.4%, respectively.

There was a higher incidence of the following AEs in the daratumumab arm than the control arm—thrombocytopenia (58.8% vs 43.9%), neutropenia (17.7% vs 9.3%), lymphopenia (13.2% vs 3.8%),  peripheral sensory neuropathy (47.3% vs 37.6%), bleeding events (7.0% vs 3.8%), and secondary primary cancers (2.5% vs 0.4%).

Infusion-related reactions associated with daratumumab were reported in 45.3% of patients. These reactions were mostly grade 1 or 2.

The percentage of patients who discontinued treatment because of at least 1 AE was similar between the daratumumab and control arms (7.4% and 9.3%, respectively).

Daratumumab (Darzalex)

Photo courtesy of Janssen

Results of the phase 3 CASTOR trial suggest that adding daratumumab to treatment with bortezomib and dexamethasone can improve progression-free survival (PFS) in patients with previously treated multiple myeloma (MM).

Compared to patients who received only bortezomib and dexamethasone, those who received daratumumab as well had a higher response rate and longer PFS, but they also had a higher incidence of grade 3/4 adverse events (AEs).

These results were recently published in NEJM. They were previously presented at the 2016 ASCO Annual Meeting. The CASTOR trial was funded by Janssen Research & Development.

The trial enrolled 498 patients with relapsed or relapsed and refractory MM. Patients were randomized to receive bortezomib (1.3 mg/m²) and dexamethasone (20 mg) alone (control arm) or in combination with daratumumab (16 mg/kg).

Baseline characteristics were well balanced between the treatment arms. Across both groups, the median patient age was 64 (range, 30 to 88), the median time since MM diagnosis was 3.8 years, and the patients had received a median of 2 (range, 1 to 10) previous lines of therapy.

Efficacy

The overall response rate was significantly higher in the daratumumab arm than the control arm—82.9% and 63.2%, respectively (P<0.001). The rate of complete response or better was higher in the daratumumab arm as well—19.2% and 9.0%, respectively (P=0.001).

After a median follow-up of 7.4 months, the median PFS was not reached in the daratumumab arm and was 7.2 months in the control arm (hazard ratio=0.39, P<0.001). The estimated 12-month PFS was 60.7% and 26.9%, respectively.

Overall survival was not reached in either treatment arm.

This trial was unblinded after meeting its primary endpoint of improved PFS in this interim analysis. Based on the recommendation of an independent data monitoring committee, patients in the control arm were offered the option to receive daratumumab following confirmed disease progression.

Safety

AEs occurred in 98.8% of patients in the daratumumab arm and 95.4% of patients in the control arm. Grade 3/4 AEs occurred in 76.1% and 62.4%, respectively.

There was a higher incidence of the following AEs in the daratumumab arm than the control arm—thrombocytopenia (58.8% vs 43.9%), neutropenia (17.7% vs 9.3%), lymphopenia (13.2% vs 3.8%),  peripheral sensory neuropathy (47.3% vs 37.6%), bleeding events (7.0% vs 3.8%), and secondary primary cancers (2.5% vs 0.4%).

Infusion-related reactions associated with daratumumab were reported in 45.3% of patients. These reactions were mostly grade 1 or 2.

The percentage of patients who discontinued treatment because of at least 1 AE was similar between the daratumumab and control arms (7.4% and 9.3%, respectively).

Daratumumab (Darzalex)

Photo courtesy of Janssen

Results of the phase 3 CASTOR trial suggest that adding daratumumab to treatment with bortezomib and dexamethasone can improve progression-free survival (PFS) in patients with previously treated multiple myeloma (MM).

Compared to patients who received only bortezomib and dexamethasone, those who received daratumumab as well had a higher response rate and longer PFS, but they also had a higher incidence of grade 3/4 adverse events (AEs).

These results were recently published in NEJM. They were previously presented at the 2016 ASCO Annual Meeting. The CASTOR trial was funded by Janssen Research & Development.

The trial enrolled 498 patients with relapsed or relapsed and refractory MM. Patients were randomized to receive bortezomib (1.3 mg/m²) and dexamethasone (20 mg) alone (control arm) or in combination with daratumumab (16 mg/kg).

Baseline characteristics were well balanced between the treatment arms. Across both groups, the median patient age was 64 (range, 30 to 88), the median time since MM diagnosis was 3.8 years, and the patients had received a median of 2 (range, 1 to 10) previous lines of therapy.

Efficacy

The overall response rate was significantly higher in the daratumumab arm than the control arm—82.9% and 63.2%, respectively (P<0.001). The rate of complete response or better was higher in the daratumumab arm as well—19.2% and 9.0%, respectively (P=0.001).

After a median follow-up of 7.4 months, the median PFS was not reached in the daratumumab arm and was 7.2 months in the control arm (hazard ratio=0.39, P<0.001). The estimated 12-month PFS was 60.7% and 26.9%, respectively.

Overall survival was not reached in either treatment arm.

This trial was unblinded after meeting its primary endpoint of improved PFS in this interim analysis. Based on the recommendation of an independent data monitoring committee, patients in the control arm were offered the option to receive daratumumab following confirmed disease progression.

Safety

AEs occurred in 98.8% of patients in the daratumumab arm and 95.4% of patients in the control arm. Grade 3/4 AEs occurred in 76.1% and 62.4%, respectively.

There was a higher incidence of the following AEs in the daratumumab arm than the control arm—thrombocytopenia (58.8% vs 43.9%), neutropenia (17.7% vs 9.3%), lymphopenia (13.2% vs 3.8%),  peripheral sensory neuropathy (47.3% vs 37.6%), bleeding events (7.0% vs 3.8%), and secondary primary cancers (2.5% vs 0.4%).

Infusion-related reactions associated with daratumumab were reported in 45.3% of patients. These reactions were mostly grade 1 or 2.

The percentage of patients who discontinued treatment because of at least 1 AE was similar between the daratumumab and control arms (7.4% and 9.3%, respectively).

DURBAN, SOUTH AFRICA – Long-acting injectable antiretroviral therapy with cabotegravir and rilpivirine in nanosuspension successfully suppressed HIV-infected patients’ plasma viral load to fewer than 50 copies/mL for 48 weeks as maintenance therapy in the LATTE-2 trial, David A. Margolis, MD, reported at the 21st International AIDS Conference.

The intramuscular gluteal injections given every 4 or 8 weeks also proved safe and extremely well tolerated. At week 48, more than 97% of patients on injectable maintenance antiretroviral therapy (ART) reported a high degree of satisfaction with their treatment regimen on a structured questionnaire and expressed a willingness to continue on injectable therapy in the future, according to Dr. Margolis of Viiv Healthcare in Research Triangle Park, N.C.

Bruce Jancin/Frontline Medical News

Cabotegravir is an HIV integrase inhibitor, rilpivirine a nonnucleoside reverse transcriptase inhibitor. Rilpivirine is already approved as Edurant, a once-daily 25-mg tablet for oral therapy. Cabotegravir is under development as a 30-mg once-daily tablet. As oral agents, each has a half-life of roughly 40 hours. The two-drug oral combination showed a high degree of safety and efficacy through 96 weeks of follow-up in the LATTE-1 study, previously reported by Dr. Margolis (Lancet Infect Dis. 2015 Oct;15[10]):1145-55) .

In addition, the two antiretroviral agents are being developed as long-acting injectables with half-lives of 20-90 days. LATTE-2 was a phase IIb, open-label, multicenter study that began with 309 HIV-positive, ART-naive subjects who participated in a 20-week induction phase during which they received 30 mg/day of oral cabotegravir plus abacavir/lamivudine to induce HIV viral suppression. During the last 4 weeks of the induction phase, participants also received oral rilpivirine at 25 mg once daily to ensure they could tolerate the drug.

At the end of the 20-week induction phase, 228 patients with an HIV viral load below 50 copies/mL were randomized 2:2:1 to maintenance therapy with intramuscular injections of long-acting cabotegravir at 200 mg/mL and long-acting rilpivirine at 300 mg/mL in nanosuspension every 4 or 8 weeks or to the oral once-daily versions of the two drugs.

After 48 weeks of maintenance therapy, an HIV RNA load of less than 50 copies/mL was present in 92% of subjects on injections every 8 weeks, 91% with injections every 4 weeks, and 89% of those on oral daily therapy. Moreover, of the eight virologic nonresponders at 48 weeks in the 8-week-injection schedule, six remained in the study and five of them have consistently achieved a viral load below 50 copies/mL in subsequent visits through week 72.

Viral failure defined as an HIV RNA viral load greater than 200 copies/mL on two occasions occurred in 1% of patients on the 8-week interval schedule, 1% of those on oral therapy, and no one on IM injections every 4 weeks. One patient on every-8-week schedule developed treatment-emergent viral resistance.

More than 80% of patients in both IM injection study arms experienced painful injection site reactions after their first treatment session, 82% of which were mild and 17% moderate. Ninety percent of these reactions resolved within 7 days; median duration was 3 days. Two patients withdrew from the study as a result of these reactions. After the first round of injections, the incidence of injection site reactions fell to 25%-30%.

Other adverse events consisted of fever, fatigue, headache, rash, and flu-like symptoms, each with an incidence of 2%-4%.

Based upon the LATTE-2 outcomes, the once-per-month injection regimen has been selected for the forthcoming pivotal phase III randomized clinical trials of long-acting cabotegravir/rilpivirine for ART, Dr. Margolis said.

The pharmaceutical industry is pursuing long-acting injectable ART both for pre-exposure prophylaxis (PrEP) and for treatment of HIV-infected patients. Clinicians and patients alike are eager for this option, especially for PrEP, where adherence to daily oral therapy has been suboptimal in many studies.

But there is a fly in the ointment. One of the most talked about studies presented at AIDS 2016 was Dr. Ian McGowan’s report that low levels of rilpivirine were found in plasma and female genital tract fluids more than 18 months after a single IM 1,200-mg dose of rilpivirine in seven participants in a long-acting PrEP study.

Bruce Jancin/Frontline Medical News

“There is certainly the possibility that extended periods of drug availability at perhaps subtherapeutic concentrations might increase the risk of ART resistance in individuals who seroconvert after exposure to long-acting PrEP,” cautioned Dr. McGowan, professor of medicine at the University of Pittsburgh.

No similar studies have as yet been done with other candidate long-acting injectables, he said.

“It’s clear, I think, that as we move forward with this exciting field of long-acting injectables we really need to better characterize the terminal half-life of these products so that we can better inform management of the pharmacokinetic tail and hopefully avoid the potential for ART resistance,” Dr. McGowan added.

His study was funded by the Bill and Melinda Gates Foundation.

Dr. Margolis is an employee of Viiv Healthcare, the LATTE-2 study sponsor.

[email protected]

DURBAN, SOUTH AFRICA – Long-acting injectable antiretroviral therapy with cabotegravir and rilpivirine in nanosuspension successfully suppressed HIV-infected patients’ plasma viral load to fewer than 50 copies/mL for 48 weeks as maintenance therapy in the LATTE-2 trial, David A. Margolis, MD, reported at the 21st International AIDS Conference.

The intramuscular gluteal injections given every 4 or 8 weeks also proved safe and extremely well tolerated. At week 48, more than 97% of patients on injectable maintenance antiretroviral therapy (ART) reported a high degree of satisfaction with their treatment regimen on a structured questionnaire and expressed a willingness to continue on injectable therapy in the future, according to Dr. Margolis of Viiv Healthcare in Research Triangle Park, N.C.

Bruce Jancin/Frontline Medical News

Cabotegravir is an HIV integrase inhibitor, rilpivirine a nonnucleoside reverse transcriptase inhibitor. Rilpivirine is already approved as Edurant, a once-daily 25-mg tablet for oral therapy. Cabotegravir is under development as a 30-mg once-daily tablet. As oral agents, each has a half-life of roughly 40 hours. The two-drug oral combination showed a high degree of safety and efficacy through 96 weeks of follow-up in the LATTE-1 study, previously reported by Dr. Margolis (Lancet Infect Dis. 2015 Oct;15[10]):1145-55) .

In addition, the two antiretroviral agents are being developed as long-acting injectables with half-lives of 20-90 days. LATTE-2 was a phase IIb, open-label, multicenter study that began with 309 HIV-positive, ART-naive subjects who participated in a 20-week induction phase during which they received 30 mg/day of oral cabotegravir plus abacavir/lamivudine to induce HIV viral suppression. During the last 4 weeks of the induction phase, participants also received oral rilpivirine at 25 mg once daily to ensure they could tolerate the drug.

At the end of the 20-week induction phase, 228 patients with an HIV viral load below 50 copies/mL were randomized 2:2:1 to maintenance therapy with intramuscular injections of long-acting cabotegravir at 200 mg/mL and long-acting rilpivirine at 300 mg/mL in nanosuspension every 4 or 8 weeks or to the oral once-daily versions of the two drugs.

After 48 weeks of maintenance therapy, an HIV RNA load of less than 50 copies/mL was present in 92% of subjects on injections every 8 weeks, 91% with injections every 4 weeks, and 89% of those on oral daily therapy. Moreover, of the eight virologic nonresponders at 48 weeks in the 8-week-injection schedule, six remained in the study and five of them have consistently achieved a viral load below 50 copies/mL in subsequent visits through week 72.

Viral failure defined as an HIV RNA viral load greater than 200 copies/mL on two occasions occurred in 1% of patients on the 8-week interval schedule, 1% of those on oral therapy, and no one on IM injections every 4 weeks. One patient on every-8-week schedule developed treatment-emergent viral resistance.

More than 80% of patients in both IM injection study arms experienced painful injection site reactions after their first treatment session, 82% of which were mild and 17% moderate. Ninety percent of these reactions resolved within 7 days; median duration was 3 days. Two patients withdrew from the study as a result of these reactions. After the first round of injections, the incidence of injection site reactions fell to 25%-30%.

Other adverse events consisted of fever, fatigue, headache, rash, and flu-like symptoms, each with an incidence of 2%-4%.

Based upon the LATTE-2 outcomes, the once-per-month injection regimen has been selected for the forthcoming pivotal phase III randomized clinical trials of long-acting cabotegravir/rilpivirine for ART, Dr. Margolis said.

The pharmaceutical industry is pursuing long-acting injectable ART both for pre-exposure prophylaxis (PrEP) and for treatment of HIV-infected patients. Clinicians and patients alike are eager for this option, especially for PrEP, where adherence to daily oral therapy has been suboptimal in many studies.

But there is a fly in the ointment. One of the most talked about studies presented at AIDS 2016 was Dr. Ian McGowan’s report that low levels of rilpivirine were found in plasma and female genital tract fluids more than 18 months after a single IM 1,200-mg dose of rilpivirine in seven participants in a long-acting PrEP study.

Bruce Jancin/Frontline Medical News

“There is certainly the possibility that extended periods of drug availability at perhaps subtherapeutic concentrations might increase the risk of ART resistance in individuals who seroconvert after exposure to long-acting PrEP,” cautioned Dr. McGowan, professor of medicine at the University of Pittsburgh.

No similar studies have as yet been done with other candidate long-acting injectables, he said.

“It’s clear, I think, that as we move forward with this exciting field of long-acting injectables we really need to better characterize the terminal half-life of these products so that we can better inform management of the pharmacokinetic tail and hopefully avoid the potential for ART resistance,” Dr. McGowan added.

His study was funded by the Bill and Melinda Gates Foundation.

Dr. Margolis is an employee of Viiv Healthcare, the LATTE-2 study sponsor.

[email protected]

DURBAN, SOUTH AFRICA – Long-acting injectable antiretroviral therapy with cabotegravir and rilpivirine in nanosuspension successfully suppressed HIV-infected patients’ plasma viral load to fewer than 50 copies/mL for 48 weeks as maintenance therapy in the LATTE-2 trial, David A. Margolis, MD, reported at the 21st International AIDS Conference.

The intramuscular gluteal injections given every 4 or 8 weeks also proved safe and extremely well tolerated. At week 48, more than 97% of patients on injectable maintenance antiretroviral therapy (ART) reported a high degree of satisfaction with their treatment regimen on a structured questionnaire and expressed a willingness to continue on injectable therapy in the future, according to Dr. Margolis of Viiv Healthcare in Research Triangle Park, N.C.

Bruce Jancin/Frontline Medical News

Cabotegravir is an HIV integrase inhibitor, rilpivirine a nonnucleoside reverse transcriptase inhibitor. Rilpivirine is already approved as Edurant, a once-daily 25-mg tablet for oral therapy. Cabotegravir is under development as a 30-mg once-daily tablet. As oral agents, each has a half-life of roughly 40 hours. The two-drug oral combination showed a high degree of safety and efficacy through 96 weeks of follow-up in the LATTE-1 study, previously reported by Dr. Margolis (Lancet Infect Dis. 2015 Oct;15[10]):1145-55) .

In addition, the two antiretroviral agents are being developed as long-acting injectables with half-lives of 20-90 days. LATTE-2 was a phase IIb, open-label, multicenter study that began with 309 HIV-positive, ART-naive subjects who participated in a 20-week induction phase during which they received 30 mg/day of oral cabotegravir plus abacavir/lamivudine to induce HIV viral suppression. During the last 4 weeks of the induction phase, participants also received oral rilpivirine at 25 mg once daily to ensure they could tolerate the drug.

At the end of the 20-week induction phase, 228 patients with an HIV viral load below 50 copies/mL were randomized 2:2:1 to maintenance therapy with intramuscular injections of long-acting cabotegravir at 200 mg/mL and long-acting rilpivirine at 300 mg/mL in nanosuspension every 4 or 8 weeks or to the oral once-daily versions of the two drugs.

After 48 weeks of maintenance therapy, an HIV RNA load of less than 50 copies/mL was present in 92% of subjects on injections every 8 weeks, 91% with injections every 4 weeks, and 89% of those on oral daily therapy. Moreover, of the eight virologic nonresponders at 48 weeks in the 8-week-injection schedule, six remained in the study and five of them have consistently achieved a viral load below 50 copies/mL in subsequent visits through week 72.

Viral failure defined as an HIV RNA viral load greater than 200 copies/mL on two occasions occurred in 1% of patients on the 8-week interval schedule, 1% of those on oral therapy, and no one on IM injections every 4 weeks. One patient on every-8-week schedule developed treatment-emergent viral resistance.

More than 80% of patients in both IM injection study arms experienced painful injection site reactions after their first treatment session, 82% of which were mild and 17% moderate. Ninety percent of these reactions resolved within 7 days; median duration was 3 days. Two patients withdrew from the study as a result of these reactions. After the first round of injections, the incidence of injection site reactions fell to 25%-30%.

Other adverse events consisted of fever, fatigue, headache, rash, and flu-like symptoms, each with an incidence of 2%-4%.

Based upon the LATTE-2 outcomes, the once-per-month injection regimen has been selected for the forthcoming pivotal phase III randomized clinical trials of long-acting cabotegravir/rilpivirine for ART, Dr. Margolis said.

The pharmaceutical industry is pursuing long-acting injectable ART both for pre-exposure prophylaxis (PrEP) and for treatment of HIV-infected patients. Clinicians and patients alike are eager for this option, especially for PrEP, where adherence to daily oral therapy has been suboptimal in many studies.

But there is a fly in the ointment. One of the most talked about studies presented at AIDS 2016 was Dr. Ian McGowan’s report that low levels of rilpivirine were found in plasma and female genital tract fluids more than 18 months after a single IM 1,200-mg dose of rilpivirine in seven participants in a long-acting PrEP study.

Bruce Jancin/Frontline Medical News

“There is certainly the possibility that extended periods of drug availability at perhaps subtherapeutic concentrations might increase the risk of ART resistance in individuals who seroconvert after exposure to long-acting PrEP,” cautioned Dr. McGowan, professor of medicine at the University of Pittsburgh.

No similar studies have as yet been done with other candidate long-acting injectables, he said.

“It’s clear, I think, that as we move forward with this exciting field of long-acting injectables we really need to better characterize the terminal half-life of these products so that we can better inform management of the pharmacokinetic tail and hopefully avoid the potential for ART resistance,” Dr. McGowan added.

His study was funded by the Bill and Melinda Gates Foundation.

Dr. Margolis is an employee of Viiv Healthcare, the LATTE-2 study sponsor.

[email protected]

Antibiotics are overprescribed in asthma-related hospitalizations, even though guidelines recommend against prescribing antibiotics during exacerbations of asthma in the absence of concurrent infection, reported Peter K. Lindenauer, MD, MSc, of Baystate Medical Center in Springfield, Mass., and his colleagues.

They examined the hospitalization records of 51,951 individuals admitted to 577 hospitals in the United States between 2013 and 2014 with a principal diagnosis of either asthma or acute respiratory failure combined with asthma as a secondary diagnosis. Each patient type and the timing of antibiotic therapy was noted.

A total of 30,226 of the 51,951 patients (58.2%) were prescribed antibiotics at some point during their hospitalization, while 21,248 (40.9%) were prescribed antibiotics on the first day of hospitalization, without “documentation of an indication for antibiotic therapy.”

Macrolides were most commonly prescribed, given to 9,633 (18.5%) of patients, followed by quinolones (8,632, 16.1%), third-generation cephalosporins (4,420, 8.5%), and tetracyclines (1,858, 3.6%). After adjustment for risk variables, chronic obstructive asthma hospitalizations were found to be those most highly associated with receiving antibiotics (odds ratio 1.6, 95% confidence interval 1.5-1.7).

“Possible explanations for this high rate of potentially inappropriate treatment include the challenge of differentiating bacterial from nonbacterial infections, distinguishing asthma from chronic obstructive pulmonary disease in the acute care setting, and gaps in knowledge about the benefits of antibiotic therapy,” the authors posited, adding that these findings “suggest a significant opportunity to improve patient safety, reduce the spread of resistance, and lower spending through greater adherence to guideline recommendations.”

The National Heart, Lung, and Blood Institute and Veterans Affairs Health Services Research and Development funded the study. Dr. Lindenauer and his coauthors did not report any relevant financial disclosures.

[email protected]

Antibiotics are overprescribed in asthma-related hospitalizations, even though guidelines recommend against prescribing antibiotics during exacerbations of asthma in the absence of concurrent infection, reported Peter K. Lindenauer, MD, MSc, of Baystate Medical Center in Springfield, Mass., and his colleagues.

They examined the hospitalization records of 51,951 individuals admitted to 577 hospitals in the United States between 2013 and 2014 with a principal diagnosis of either asthma or acute respiratory failure combined with asthma as a secondary diagnosis. Each patient type and the timing of antibiotic therapy was noted.

A total of 30,226 of the 51,951 patients (58.2%) were prescribed antibiotics at some point during their hospitalization, while 21,248 (40.9%) were prescribed antibiotics on the first day of hospitalization, without “documentation of an indication for antibiotic therapy.”

Macrolides were most commonly prescribed, given to 9,633 (18.5%) of patients, followed by quinolones (8,632, 16.1%), third-generation cephalosporins (4,420, 8.5%), and tetracyclines (1,858, 3.6%). After adjustment for risk variables, chronic obstructive asthma hospitalizations were found to be those most highly associated with receiving antibiotics (odds ratio 1.6, 95% confidence interval 1.5-1.7).

“Possible explanations for this high rate of potentially inappropriate treatment include the challenge of differentiating bacterial from nonbacterial infections, distinguishing asthma from chronic obstructive pulmonary disease in the acute care setting, and gaps in knowledge about the benefits of antibiotic therapy,” the authors posited, adding that these findings “suggest a significant opportunity to improve patient safety, reduce the spread of resistance, and lower spending through greater adherence to guideline recommendations.”

The National Heart, Lung, and Blood Institute and Veterans Affairs Health Services Research and Development funded the study. Dr. Lindenauer and his coauthors did not report any relevant financial disclosures.

[email protected]

Antibiotics are overprescribed in asthma-related hospitalizations, even though guidelines recommend against prescribing antibiotics during exacerbations of asthma in the absence of concurrent infection, reported Peter K. Lindenauer, MD, MSc, of Baystate Medical Center in Springfield, Mass., and his colleagues.

They examined the hospitalization records of 51,951 individuals admitted to 577 hospitals in the United States between 2013 and 2014 with a principal diagnosis of either asthma or acute respiratory failure combined with asthma as a secondary diagnosis. Each patient type and the timing of antibiotic therapy was noted.

A total of 30,226 of the 51,951 patients (58.2%) were prescribed antibiotics at some point during their hospitalization, while 21,248 (40.9%) were prescribed antibiotics on the first day of hospitalization, without “documentation of an indication for antibiotic therapy.”

Macrolides were most commonly prescribed, given to 9,633 (18.5%) of patients, followed by quinolones (8,632, 16.1%), third-generation cephalosporins (4,420, 8.5%), and tetracyclines (1,858, 3.6%). After adjustment for risk variables, chronic obstructive asthma hospitalizations were found to be those most highly associated with receiving antibiotics (odds ratio 1.6, 95% confidence interval 1.5-1.7).

“Possible explanations for this high rate of potentially inappropriate treatment include the challenge of differentiating bacterial from nonbacterial infections, distinguishing asthma from chronic obstructive pulmonary disease in the acute care setting, and gaps in knowledge about the benefits of antibiotic therapy,” the authors posited, adding that these findings “suggest a significant opportunity to improve patient safety, reduce the spread of resistance, and lower spending through greater adherence to guideline recommendations.”

The National Heart, Lung, and Blood Institute and Veterans Affairs Health Services Research and Development funded the study. Dr. Lindenauer and his coauthors did not report any relevant financial disclosures.

[email protected]

Daratumumab significantly improved survival when added to the current two-drug regimen for multiple myeloma, according to published data from a phase III study.

Patients treated with the anti-CD38 antibody in addition to the current standard treatment combination of bortezomib and dexamethasone had a 61% progression-free survival rate compared with a 27% rate seen in controls who received only bortezomib and dexamethasone.

The study results were presented initially at the annual meeting of the American Society of Hematology in 2015.

After an average follow-up of 7 months, 67 disease-progression events or deaths occurred in the daratumumab group, compared with 122 in the control group. Overall treatment response rates also were significantly higher in the daratumumab group compared with controls (83% vs. 63%), reported Antonio Palumbo, MD, of the University of Turin, Italy, and his associates in the CASTOR study.

The multicenter, randomized trial included 251 multiple myeloma patients in the daratumumab group 247 patients in the control group. Demographics were similar between the groups; the median patient age was 64 years.

Although more than 95% of patients in each group reported at least one adverse event, fewer than 10% of patients in each group discontinued treatment as a result. The most common adverse events associated with discontinuation were peripheral sensory neuropathy and pneumonia (N Engl J Med 2016;375:754-66).

The study was funded by Janssen Research and Development.

Daratumumab significantly improved survival when added to the current two-drug regimen for multiple myeloma, according to published data from a phase III study.

Patients treated with the anti-CD38 antibody in addition to the current standard treatment combination of bortezomib and dexamethasone had a 61% progression-free survival rate compared with a 27% rate seen in controls who received only bortezomib and dexamethasone.

The study results were presented initially at the annual meeting of the American Society of Hematology in 2015.

After an average follow-up of 7 months, 67 disease-progression events or deaths occurred in the daratumumab group, compared with 122 in the control group. Overall treatment response rates also were significantly higher in the daratumumab group compared with controls (83% vs. 63%), reported Antonio Palumbo, MD, of the University of Turin, Italy, and his associates in the CASTOR study.

The multicenter, randomized trial included 251 multiple myeloma patients in the daratumumab group 247 patients in the control group. Demographics were similar between the groups; the median patient age was 64 years.

Although more than 95% of patients in each group reported at least one adverse event, fewer than 10% of patients in each group discontinued treatment as a result. The most common adverse events associated with discontinuation were peripheral sensory neuropathy and pneumonia (N Engl J Med 2016;375:754-66).

The study was funded by Janssen Research and Development.

Daratumumab significantly improved survival when added to the current two-drug regimen for multiple myeloma, according to published data from a phase III study.

Patients treated with the anti-CD38 antibody in addition to the current standard treatment combination of bortezomib and dexamethasone had a 61% progression-free survival rate compared with a 27% rate seen in controls who received only bortezomib and dexamethasone.

The study results were presented initially at the annual meeting of the American Society of Hematology in 2015.

After an average follow-up of 7 months, 67 disease-progression events or deaths occurred in the daratumumab group, compared with 122 in the control group. Overall treatment response rates also were significantly higher in the daratumumab group compared with controls (83% vs. 63%), reported Antonio Palumbo, MD, of the University of Turin, Italy, and his associates in the CASTOR study.

The multicenter, randomized trial included 251 multiple myeloma patients in the daratumumab group 247 patients in the control group. Demographics were similar between the groups; the median patient age was 64 years.

Although more than 95% of patients in each group reported at least one adverse event, fewer than 10% of patients in each group discontinued treatment as a result. The most common adverse events associated with discontinuation were peripheral sensory neuropathy and pneumonia (N Engl J Med 2016;375:754-66).

The study was funded by Janssen Research and Development.

Major depressive disorder is associated with a significant increase in the risk of acute myocardial infarction in adults infected with HIV, even after accounting for existing cardiovascular and HIV-related risk factors, according to research published online Aug. 24 in JAMA Cardiology.

Researchers conducted a retrospective analysis of data from 26,144 HIV-infected veterans participating in the U.S. Department of Veterans Affairs Veterans Aging Cohort Study. Among these veterans, 4,853 (19%) had major depressive disorder and 2,296 (9%) had dysthymic disorder.

After adjustment for cardiovascular risk factors such as hypertension and lipid levels, HIV-infected individuals with major depressive disorder had a 29% higher risk of acute MI compared with HIV-infected individuals without major depressive disorder.

This association remained at the same level but lost its statistical significance after adjustment for hepatitis C infection, renal disease, and alcohol or cocaine dependence (JAMA Cardiology 2016, Aug 24. doi: 10.1001/jamacardio.2016.2716).

Acute myocardial event risk was not significantly increased in HIV-infected individuals with dysthymic disorder, although the hazard ratios themselves were only slightly smaller than those of people with major depressive disorder.

Depression is a known independent risk factor for cardiovascular disease; the authors cited one meta-analysis of 16 studies in the general population that suggested a 57% increase in cardiovascular risk associated with depression.

“Similar to the general population, MDD may be independently associated with incident atherosclerotic CVD in the HIV infected population,” wrote Tasneem Khambaty, PhD, of the University of Miami, and coauthors.

“Given the greater risk for CVD of HIV-infected adults and adults with depression separately and the high prevalence (24%-40%) of depressive disorders in those with HIV, a key remaining question is the following: Is depression independently associated with incident atherosclerotic CVD in the HIV infected population?” the authors asked.

The same mechanisms that increase the risk of cardiovascular disease with depression in the general population also appear to be at play in individuals with HIV, the authors said.

Certain HIV medications such as efavirenz have been independently associated with depression, suicidality, and an increased risk of acute MI events, although researchers said this would not have accounted for the increase in risk observed in this study.

The Veterans Aging Cohort Study was funded by the National Institute on Alcohol Abuse and Alcoholism, and Veterans Health Administration Public Health Strategic Health Core Group, and this analysis was partly supported by funding from the National Institutes of Health. Two authors declared grants and other funding from pharmaceutical companies, two declared grants from the National Institutes of Health, and one author disclosed a grant from General Electric. No other conflicts of interest were disclosed.

Major depressive disorder is associated with a significant increase in the risk of acute myocardial infarction in adults infected with HIV, even after accounting for existing cardiovascular and HIV-related risk factors, according to research published online Aug. 24 in JAMA Cardiology.

Researchers conducted a retrospective analysis of data from 26,144 HIV-infected veterans participating in the U.S. Department of Veterans Affairs Veterans Aging Cohort Study. Among these veterans, 4,853 (19%) had major depressive disorder and 2,296 (9%) had dysthymic disorder.

After adjustment for cardiovascular risk factors such as hypertension and lipid levels, HIV-infected individuals with major depressive disorder had a 29% higher risk of acute MI compared with HIV-infected individuals without major depressive disorder.

This association remained at the same level but lost its statistical significance after adjustment for hepatitis C infection, renal disease, and alcohol or cocaine dependence (JAMA Cardiology 2016, Aug 24. doi: 10.1001/jamacardio.2016.2716).

Acute myocardial event risk was not significantly increased in HIV-infected individuals with dysthymic disorder, although the hazard ratios themselves were only slightly smaller than those of people with major depressive disorder.

Depression is a known independent risk factor for cardiovascular disease; the authors cited one meta-analysis of 16 studies in the general population that suggested a 57% increase in cardiovascular risk associated with depression.

“Similar to the general population, MDD may be independently associated with incident atherosclerotic CVD in the HIV infected population,” wrote Tasneem Khambaty, PhD, of the University of Miami, and coauthors.

“Given the greater risk for CVD of HIV-infected adults and adults with depression separately and the high prevalence (24%-40%) of depressive disorders in those with HIV, a key remaining question is the following: Is depression independently associated with incident atherosclerotic CVD in the HIV infected population?” the authors asked.

The same mechanisms that increase the risk of cardiovascular disease with depression in the general population also appear to be at play in individuals with HIV, the authors said.

Certain HIV medications such as efavirenz have been independently associated with depression, suicidality, and an increased risk of acute MI events, although researchers said this would not have accounted for the increase in risk observed in this study.

The Veterans Aging Cohort Study was funded by the National Institute on Alcohol Abuse and Alcoholism, and Veterans Health Administration Public Health Strategic Health Core Group, and this analysis was partly supported by funding from the National Institutes of Health. Two authors declared grants and other funding from pharmaceutical companies, two declared grants from the National Institutes of Health, and one author disclosed a grant from General Electric. No other conflicts of interest were disclosed.

Major depressive disorder is associated with a significant increase in the risk of acute myocardial infarction in adults infected with HIV, even after accounting for existing cardiovascular and HIV-related risk factors, according to research published online Aug. 24 in JAMA Cardiology.

Researchers conducted a retrospective analysis of data from 26,144 HIV-infected veterans participating in the U.S. Department of Veterans Affairs Veterans Aging Cohort Study. Among these veterans, 4,853 (19%) had major depressive disorder and 2,296 (9%) had dysthymic disorder.

After adjustment for cardiovascular risk factors such as hypertension and lipid levels, HIV-infected individuals with major depressive disorder had a 29% higher risk of acute MI compared with HIV-infected individuals without major depressive disorder.

This association remained at the same level but lost its statistical significance after adjustment for hepatitis C infection, renal disease, and alcohol or cocaine dependence (JAMA Cardiology 2016, Aug 24. doi: 10.1001/jamacardio.2016.2716).

Acute myocardial event risk was not significantly increased in HIV-infected individuals with dysthymic disorder, although the hazard ratios themselves were only slightly smaller than those of people with major depressive disorder.

Depression is a known independent risk factor for cardiovascular disease; the authors cited one meta-analysis of 16 studies in the general population that suggested a 57% increase in cardiovascular risk associated with depression.

“Similar to the general population, MDD may be independently associated with incident atherosclerotic CVD in the HIV infected population,” wrote Tasneem Khambaty, PhD, of the University of Miami, and coauthors.

“Given the greater risk for CVD of HIV-infected adults and adults with depression separately and the high prevalence (24%-40%) of depressive disorders in those with HIV, a key remaining question is the following: Is depression independently associated with incident atherosclerotic CVD in the HIV infected population?” the authors asked.

The same mechanisms that increase the risk of cardiovascular disease with depression in the general population also appear to be at play in individuals with HIV, the authors said.

Certain HIV medications such as efavirenz have been independently associated with depression, suicidality, and an increased risk of acute MI events, although researchers said this would not have accounted for the increase in risk observed in this study.

The Veterans Aging Cohort Study was funded by the National Institute on Alcohol Abuse and Alcoholism, and Veterans Health Administration Public Health Strategic Health Core Group, and this analysis was partly supported by funding from the National Institutes of Health. Two authors declared grants and other funding from pharmaceutical companies, two declared grants from the National Institutes of Health, and one author disclosed a grant from General Electric. No other conflicts of interest were disclosed.

Adults with moderate to severe sleep apnea and coronary or cerebrovascular disease had about the same frequency of cardiovascular events whether they received continuous positive airway pressure (CPAP) therapy or usual care alone, according to a large randomized trial.

But CPAP was used for only 3.3 hours per night by these patients and might have been “insufficient to provide the level of effect on cardiovascular outcomes that had been hypothesized,” Dr. Doug McEvoy of the Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia and his associates reported at the annual congress of the European Society of Cardiology. Their study was simultaneously published in the New England Journal of Medicine (N Engl J Med. 2016 Aug 28. doi: 10.1056/NEJMoa1606599).

Notably, CPAP did show a trend toward significance in a prespecified subgroup analysis that matched 561 patients who used CPAP for a longer period – more than 4 hours a night – with the same number of controls (hazard ratio, 0.8; 95% CI, 0.6 to 1.1; P = .1). Dr. McEvoy discussed the implications of prolonged CPAP use in a video interview with Bruce Jancin, our reporter at the ESC Congress in Rome.

Obstructive sleep apnea causes episodic hypoxemia, sympathetic nervous system activation; intrathoracic pressure swings strain the heart and great vessels, and increases markers of oxidative stress, hypercoagulation, and inflammation. Randomized trials have linked CPAP therapy to lower systolic blood pressure measures and improved endothelial function and insulin sensitivity. Observational studies suggest that CPAP might help prevent cardiovascular events and death if used consistently, the investigators noted.

Because cardiovascular disease and obstructive sleep apnea often co-occur, the researchers carried out a secondary prevention trial, Sleep Apnea Cardiovascular Endpoints (SAVE), to quantify rates of major cardiovascular events among 2,717 adults aged 45-75 years with obstructive sleep apnea and established coronary or cerebrovascular disease. Patients were randomly assigned to receive CPAP therapy plus usual care, or usual care alone. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or hospitalization from unstable angina, transient ischemic attack, or heart failure. The researchers also looked at other cardiovascular outcomes, snoring symptoms, mood, daytime sleepiness, and health-related quality of life. They used a 1-week run-in period of sham CPAP (administered at subtherapeutic pressure) to ensure what they considered an adequate level of adherence.

The average apnea-hypopnea index (that is, the average number of apnea or hypopnea events recorded per hour) was 29 at baseline and 3.7 after initiating CPAP, the investigators said. At a mean of 3.7 years of follow-up, 17% of CPAP users (220 patients) and 15.4% of controls had a cardiovascular event, for a hazard ratio of 1.1 (95% confidence interval, 0.9 to 1.3; P = 0.3).

Not only did CPAP fail to meet the composite primary endpoint, but it did not significantly affect any cause-specific cardiovascular outcome, the researchers said. However, CPAP users did improve significantly more than controls on measures of daytime sleepiness (the Epworth Sleepiness Scale), anxiety and depression (Hospital Anxiety and Depression Scale), self-reported physical and mental health (Short-Form Health Survey), and quality of life (European Quality of Life-5 Dimensions questionnaire). They also missed fewer days of work than did controls.

Study funders included the National Health and Medical Research Council of Australia, Respironics Sleep and Respiratory Research Foundation, and Phillips Respironics. Dr. McEvoy reported receiving research equipment for the study from AirLiquide. Several coinvestigators reported other ties to industry.

Adults with moderate to severe sleep apnea and coronary or cerebrovascular disease had about the same frequency of cardiovascular events whether they received continuous positive airway pressure (CPAP) therapy or usual care alone, according to a large randomized trial.

But CPAP was used for only 3.3 hours per night by these patients and might have been “insufficient to provide the level of effect on cardiovascular outcomes that had been hypothesized,” Dr. Doug McEvoy of the Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia and his associates reported at the annual congress of the European Society of Cardiology. Their study was simultaneously published in the New England Journal of Medicine (N Engl J Med. 2016 Aug 28. doi: 10.1056/NEJMoa1606599).

Notably, CPAP did show a trend toward significance in a prespecified subgroup analysis that matched 561 patients who used CPAP for a longer period – more than 4 hours a night – with the same number of controls (hazard ratio, 0.8; 95% CI, 0.6 to 1.1; P = .1). Dr. McEvoy discussed the implications of prolonged CPAP use in a video interview with Bruce Jancin, our reporter at the ESC Congress in Rome.

Obstructive sleep apnea causes episodic hypoxemia, sympathetic nervous system activation; intrathoracic pressure swings strain the heart and great vessels, and increases markers of oxidative stress, hypercoagulation, and inflammation. Randomized trials have linked CPAP therapy to lower systolic blood pressure measures and improved endothelial function and insulin sensitivity. Observational studies suggest that CPAP might help prevent cardiovascular events and death if used consistently, the investigators noted.

Because cardiovascular disease and obstructive sleep apnea often co-occur, the researchers carried out a secondary prevention trial, Sleep Apnea Cardiovascular Endpoints (SAVE), to quantify rates of major cardiovascular events among 2,717 adults aged 45-75 years with obstructive sleep apnea and established coronary or cerebrovascular disease. Patients were randomly assigned to receive CPAP therapy plus usual care, or usual care alone. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or hospitalization from unstable angina, transient ischemic attack, or heart failure. The researchers also looked at other cardiovascular outcomes, snoring symptoms, mood, daytime sleepiness, and health-related quality of life. They used a 1-week run-in period of sham CPAP (administered at subtherapeutic pressure) to ensure what they considered an adequate level of adherence.

The average apnea-hypopnea index (that is, the average number of apnea or hypopnea events recorded per hour) was 29 at baseline and 3.7 after initiating CPAP, the investigators said. At a mean of 3.7 years of follow-up, 17% of CPAP users (220 patients) and 15.4% of controls had a cardiovascular event, for a hazard ratio of 1.1 (95% confidence interval, 0.9 to 1.3; P = 0.3).

Not only did CPAP fail to meet the composite primary endpoint, but it did not significantly affect any cause-specific cardiovascular outcome, the researchers said. However, CPAP users did improve significantly more than controls on measures of daytime sleepiness (the Epworth Sleepiness Scale), anxiety and depression (Hospital Anxiety and Depression Scale), self-reported physical and mental health (Short-Form Health Survey), and quality of life (European Quality of Life-5 Dimensions questionnaire). They also missed fewer days of work than did controls.

Study funders included the National Health and Medical Research Council of Australia, Respironics Sleep and Respiratory Research Foundation, and Phillips Respironics. Dr. McEvoy reported receiving research equipment for the study from AirLiquide. Several coinvestigators reported other ties to industry.

Adults with moderate to severe sleep apnea and coronary or cerebrovascular disease had about the same frequency of cardiovascular events whether they received continuous positive airway pressure (CPAP) therapy or usual care alone, according to a large randomized trial.

But CPAP was used for only 3.3 hours per night by these patients and might have been “insufficient to provide the level of effect on cardiovascular outcomes that had been hypothesized,” Dr. Doug McEvoy of the Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia and his associates reported at the annual congress of the European Society of Cardiology. Their study was simultaneously published in the New England Journal of Medicine (N Engl J Med. 2016 Aug 28. doi: 10.1056/NEJMoa1606599).

Notably, CPAP did show a trend toward significance in a prespecified subgroup analysis that matched 561 patients who used CPAP for a longer period – more than 4 hours a night – with the same number of controls (hazard ratio, 0.8; 95% CI, 0.6 to 1.1; P = .1). Dr. McEvoy discussed the implications of prolonged CPAP use in a video interview with Bruce Jancin, our reporter at the ESC Congress in Rome.

Obstructive sleep apnea causes episodic hypoxemia, sympathetic nervous system activation; intrathoracic pressure swings strain the heart and great vessels, and increases markers of oxidative stress, hypercoagulation, and inflammation. Randomized trials have linked CPAP therapy to lower systolic blood pressure measures and improved endothelial function and insulin sensitivity. Observational studies suggest that CPAP might help prevent cardiovascular events and death if used consistently, the investigators noted.

Because cardiovascular disease and obstructive sleep apnea often co-occur, the researchers carried out a secondary prevention trial, Sleep Apnea Cardiovascular Endpoints (SAVE), to quantify rates of major cardiovascular events among 2,717 adults aged 45-75 years with obstructive sleep apnea and established coronary or cerebrovascular disease. Patients were randomly assigned to receive CPAP therapy plus usual care, or usual care alone. The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or hospitalization from unstable angina, transient ischemic attack, or heart failure. The researchers also looked at other cardiovascular outcomes, snoring symptoms, mood, daytime sleepiness, and health-related quality of life. They used a 1-week run-in period of sham CPAP (administered at subtherapeutic pressure) to ensure what they considered an adequate level of adherence.

The average apnea-hypopnea index (that is, the average number of apnea or hypopnea events recorded per hour) was 29 at baseline and 3.7 after initiating CPAP, the investigators said. At a mean of 3.7 years of follow-up, 17% of CPAP users (220 patients) and 15.4% of controls had a cardiovascular event, for a hazard ratio of 1.1 (95% confidence interval, 0.9 to 1.3; P = 0.3).

Not only did CPAP fail to meet the composite primary endpoint, but it did not significantly affect any cause-specific cardiovascular outcome, the researchers said. However, CPAP users did improve significantly more than controls on measures of daytime sleepiness (the Epworth Sleepiness Scale), anxiety and depression (Hospital Anxiety and Depression Scale), self-reported physical and mental health (Short-Form Health Survey), and quality of life (European Quality of Life-5 Dimensions questionnaire). They also missed fewer days of work than did controls.

Study funders included the National Health and Medical Research Council of Australia, Respironics Sleep and Respiratory Research Foundation, and Phillips Respironics. Dr. McEvoy reported receiving research equipment for the study from AirLiquide. Several coinvestigators reported other ties to industry.